Rossi: Progress on E-Cat SKL “Excellent”

There’s an encouraging comment by Andrea Rossi on the Journal of Nuclear Physics today in response to a question asking about what he is doing with the E-Cat SKL in the present time, and whether the coronavirus situation has caused delays.

Andrea Rossi
November 30, 2020 at 4:44 AM
The Covid has caused delays, but not in the measure necessary to create relevant damages.
Preesently I am working in remote with all the Team and I work in a laboratory testing the Ecat to consolidate the reliability of the device.
I dare to define the progress excellent, both under the experimental point of view and under the theoretical point of view.
Warm Regards,

Excellent is not a normal adjective that Rossi uses when asked about how his work is going. Typically he emphasizes the need to work hard and work through problems, etc. Maybe this is why he was prompted to make a promise that the presentation would be held in 2021.

Regarding the presentation, I recently asked whether it has been decided yet what will be shown when the presentation is held. He replied, “moreless yes”.

Brilliant Light Power Video: “SunCell First Internal Field Trial”

This video from Brilliant Light Power was published on their YouTube channel on September 15 2020. It is titled “SunCell First Internal Field Trial”

From the video description:

“Specifically, we ran the first internal field trial of our 250-kW thermal reactor with a molten gallium to water heat transfer system to produce boiling water and steam on a continuous basis for the planned 45-minute duration of the trial. A real time excerpt of 20% of the run time is shown in this video. Inspection of the SunCell following the run showed that it was in mint condition and ready for the next trial. We plan to run a series of internal field trials in preparation for deploying SunCells to commercial customers to perform field trials in their facilities.”

BrLP claims that the SunCell has a power density of 5 MW/liter, surpassing the power density of fossil fuels, and that it can be deployed in situtions where there is no grid connection or available fuel infrastructure.

Georgia Tech Research Scientist: LENR Research is ‘Serious Scientific Work’

Thanks to Teppo for pointing out a new article posted on the Medium website titled ‘“Cold Fusion” may not be fusion: Low Energy Nuclear Reaction research continues on the fringes’ written by Tim Anderson who is Principal Research Scientist at Georgia Tech (in Atlanta, Georgia, USA).

Anderson takes the phenomenon of LENR seriously and acknowledges that since the early days of Pons and Fleischmann, ‘hundreds’ of experiments have shown the production of excess heat, and ‘dozens’ have produced transmutation of elements and production of tritium.

He pays particular attention to the experiments done at the US Space and Naval Warfare Center (SPAWAR) in which researchers discovered neutron production in a deuterium/palladium electrolysis experiment.

He seems to be convinced that LENR is a field worth exploring, which is quite refreshing to hear from a research scientist at a public institution. His article concludes with this:

“In conclusion, as with the early attempts to achieve powered flight, we must both understand the mechanics and be able to produce a reliable technology to exploit it for the common good. Even then, there is a lot we don’t know. What is clear is that the work being done is serious scientific work, even if it operates on the fringes of acceptable scientific research.”

COVID-19 Thread 4/16/2020 (Clincal Trial Shows Drug Remdesivir Effective Treatment)

An article on the Statnews website reports about some apparent success treating COVID-19 patients with the Gilead drug remdesivir in a clinical trial at a Chicago hospital.

From the article:

‘The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.

‘“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital.’

The full article can be read here:

This report has apparently contributed to steep gains in stock market futures in the U.S. financials markets ahead of Friday’s market opening.

COVID-19 Thread 4/8/2020 — Testing of BCG (Baccillus-C-G) Vaccine as Possible Protection

Thanks to Sandy_r for the following submission:

It’s been observed that some nations appear to be responding with a greater resistance to COVID-19 than others – particularly interesting is the difference between adjacent countries such as Spain and Portugal (Population ratio 5:1; COVID-19 mortality ratio 55:1)

One possible contributing factor is the historic adoption of the BCG (Baccillus-C-G) vaccine against Tuberculosis

Placebo-controlled trials are currently underway in Australia and the Netherlands – from the articles:-

“On Monday, scientists in Melbourne, Australia, started administering the B.C.G. vaccine or a placebo to thousands of physicians, nurses, respiratory therapists and other health care workers — the first of several randomized controlled trials intended to test the vaccine’s effectiveness against the coronavirus.

“Nobody is saying this is a panacea,” said Nigel Curtis, an infectious diseases researcher at the University of Melbourne and Murdoch Children’s Research Institute, who planned the trial. “What we want to do is reduce the time an infected health care worker is unwell, so they recover and can come back to work faster.”

A clinical trial of 1,000 health care workers began 10 days ago in the Netherlands, said Dr. Mihai G. Netea, an infectious disease specialist at Radboud University Medical Center in Nijmegen. Eight hundred health care workers have already signed up. (As in Australia, half of the participants will receive a placebo.)

Dr. Denise Faustman, director of immunobiology at Massachusetts General Hospital, is seeking funding to start a clinical trial of the vaccine in health care workers in Boston as well. Preliminary results could be available in as little as four months.

“We have really strong data from clinical trials with humans — not mice — that this vaccine protects you from viral and parasitic infections,” said Dr. Faustman. “I’d like to start today.”

Overview article considering current global perspectives:

Background article covering BCG legacy in more detail:

4/3/2020 (Study: Anti-Parasitic Drug Kills Covid-19 in Lab)

Various news outlets are reporting about a study at Monash University in Melbourne in which researchers found that a dose of Ivermectin, a drug normally used to treat parasitic infections such as head lice and and scabies, can kill the coronavirus SARS-CoV-2 virus in test tubes.

Here is a quote from the Monash University Press Release about the study:

The Monash Biomedicine Discovery Institute’s Dr Kylie Wagstaff, who led the study, said the scientists showed that the drug, Ivermectin, stopped the SARS-CoV-2 virus growing in cell culture within 48 hours.

“We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” Dr Wagstaff said.

Ivermectin is an FDA-approved anti-parasitic drug that has also been shown to be effective in vitro against a broad range of viruses including HIV, Dengue, Influenza and Zika virus.

Dr Wagstaff cautioned that the tests conducted in the study were in vitro and that trials needed to be carried out in people.

“Ivermectin is very widely used and seen as a safe drug. We need to figure out now whether the dosage you can use it at in humans will be effective – that’s the next step,” Dr Wagstaff said.

Full text of the press release is available here:

Paper: “Lattice Dilation of Plasma Sprayed Nickel Film Quantified by High Resolution Terahertz Imaging” (Rahman, Tanzella, Rahman, Page and Godes)

Thanks to LION for posting a link to this article by Anis Rahman, Francis Tanzella, Aunik K Rahman, Carl Page and Robert Godes, titled “Lattice Dilation of Plasma Sprayed Nickel Film Quantified by High Resolution Terahertz Imaging”.

From the Conclusion section:

A model has been proposed for explaining the increased heat energy generation from IPB-HHT experiment with the LENR tube cells. Here the fluid-like nickel lattice at higher temperatures, and under the influence of an RF electric field, is assumed to undergo a space-time crystal like non-equilibrium effect; and thus, producing increased energy via a non-radiative transition process. An in-situ monitoring of the IPB-HHT experiment has been proposed to determine the correlation between the excess energy generation period and the observed lattice dilation.



Assessment of Rossi and the E-Cat (Mats Lewan)

Thanks to Mats Lewan for this comment on his thoughts about the current state of affairs regarding Andrea Rossi and the E-Cat (provided in response to Bruce Williams in this thread

Bruce – it is difficult to report on Rossi’s activities at the moment since there’s no confirmed news. At all. However, lately I have been regularly in contact with Rossi, and I have also gone through large parts of the documentation from the court case. I start to have a clearer idea on what really happened, and why everyone reacted as they did, including IH. Will try to confirm my hypothesis and report on it some day.

The conclusion and my assessment, in any case, is that Rossi has what he claims. First, nothing else makes sense. Second, what Rossi tells me keeps making sense (theory, experiments, efforts, ambitions, behaviour, doubts, etc etc).

I don’t know anything about his ongoing sales of heat to customers. I have the impression that he is very careful about letting customers in, while also being strongly focused on the R&D of SSM.
I also think he could be ready to do a convincing demo (significantly easier with SSM since there’s no input at all), maybe closed, which could move some things.

At that point comes the question on how to diffuse the technology to the world in an efficient way. I have my opinions and I’m ready to help if I get the opportunity. From my point of view, this amazing story is continuing, and I’m still curious about where it will lead.

Yet, I understand that as an outside observer, without talking with Rossi, it’s very difficult to get a reasonably solid idea on what he is doing. Which is why it will come as a complete surprise to the world if he one days presents a solid and viable technology.

A few days ago I went to a presentation by Nassim Nicholas Taleb about his new book, Skin in the Game. I refer to his book The Black Swan in my book, and I will try to send him a copy. Probably he won’t read it, but if he does I would be curious about his view on the situation. Viable LENR is so far from most people’s imagination that it would by all means be a black swan. Therefore, before bringing such technology to the world, however useful it might be, some work would need to be done in order to make it come to good use.

ICCF22 – Celani – Progress in Anomalous Heat Effects using Constantan and D2

Thanks to Bob Greenyer for another interesting report from ICCF-22.

ICCF22 – Celani – Progress in Anomalous Heat Effects using Constantan and D2 – Italy 2019

Progresses on understanding LENR-AHE effects, using thin and long Constantan wires multi-elements coated, under D2 gas mixtures at high temperatures, by DC/AC Voltage stimulation in coiled coaxial geometry.

Slides can be downloaded from here:

Below is the slide titled “Conclusions”

Rossi: Weeks-long Testing for on Permanent SSM to Start August

A comment by Andrea Rossi on the Journal of Nuclear Physics outlines the schedule of a new round of testing that is planned for the upcoming weeks:

Andrea Rossi
August 9, 2019 at 10:53 PM
Working with the Ecat SK Leonardo. Preparing the very important tests that will start on August 22 and will end at the beginning of October: after that phase we will know if the permanent SSM revolution will succeed or not. The work is hard and difficult, the matter very complex, but I am working with the best possible Team in this matter in the whole world.
I am optimist, but this is a fight.
A very hard fight.
Warm Regards,

To me, Andrea does not sound particularly confident here about achieving ‘permanent self-sustained mechanism’ with the E-Cat SK. It seems like getting a sufficient amount of direct electricity production from the SK plasma, enough to charge a battery is proving to be quite a challenge.

And I am not sure how urgent a problem this is to solve if the E-Cat SK works well. It would seem that if it actually can run from a battery, it would be simpler to have the battery charged in a conventional manner, not necessarily charged by the E-Cat itself. It would be elegant and impressive if the E-Cat could be completely stand-alone, but not necessary from a commercial point of view.